PARP Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Tyrosine Kinase Inhibitors Epigenetics Other PI3 Kinase Inhibitors Proteasome Inhibitors BCL Inhibitors Chemotherapy | Ovarian Cancer | Triple Negative Breast Cancer | HER2 Negative Breast Cancer | Breast Cancer |
---|---|---|---|---|
rucaparib | ||||
ABT-888 | ||||
bevacizumab + olaparib + durvalumab | ||||
AZD1775 | ||||
olaparib + alpelisib | ||||
talazoparib | ||||
ACR-368 | ||||
pembrolizumab + bevacizumab + olaparib | ||||
talazoparib + ZEN-3694 | ||||
bortezomib | ||||
carboplatin + paclitaxel | ||||
bevacizumab + olaparib + atezolizumab | ||||
carboplatin + paclitaxel + cyclophosphamide | ||||
DAN-222 | ||||
niraparib + DAN-222 | ||||
MLN4924 | ||||
olaparib | ||||
olaparib + cediranib + 3-AP | ||||
olaparib + AZD1775 |